|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Ferlay J, van Berge Henegouwen
MI and Soerjomataram I: Global burden of oesophageal and gastric
cancer by histology and subsite in 2018. Gut. 69:1564–1571. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tramontano AC, Chen Y, Watson TR, Eckel A,
Hur C and Kong CY: Esophageal cancer treatment costs by phase of
care and treatment modality, 2000–2013. Cancer Med. 8:5158–5172.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey
SM, Dong ZW, Mark SD, Qiao YL and Taylor PR: Prospective study of
risk factors for esophageal and gastric cancers in the Linxian
general population trial cohort in China. Int J Cancer.
113:456–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun
ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al: Genetic landscape of
esophageal squamous cell carcinoma. Nat Genet. 46:1097–1102. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thrift AP: Global burden and epidemiology
of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol
Hepatol. 18:432–443. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung J, Jeong H, Choi JW, Kim HS, Oh HE,
Lee ES, Kim YS and Lee JH: Increased expression levels of AURKA and
KIFC1 are promising predictors of progression and poor survival
associated with gastric cancer. Pathol Res Pract. 224:1535242021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Martino M, Shariat SF, Hofbauer SL,
Lucca I, Taus C, Wiener HG, Haitel A, Susani M and Klatte T: Aurora
A kinase as a diagnostic urinary marker for urothelial bladder
cancer. World J Urol. 33:105–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyoshi Y, Iwao K, Egawa C and Noguchi S:
Association of centrosomal kinase STK15/BTAK mRNA expression with
chromosomal instability in human breast cancers. Int J Cancer.
92:370–373. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Belt EJ, Brosens RP, Delis-van Diemen PM,
Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann
HB, Meijer S and Meijer GA: Cell cycle proteins predict recurrence
in stage II and III colon cancer. Ann Surg Oncol. 19 (Suppl
3):S682–S692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang G, Chang B, Yang F, Guo X, Cai KQ,
Xiao XS, Wang H, Sen S, Hung MC, Mills GB, et al: Aurora kinase A
promotes ovarian tumorigenesis through dysregulation of the cell
cycle and suppression of BRCA2. Clin Cancer Res. 16:3171–3181.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du R, Huang C, Liu K, Li X and Dong Z:
Targeting AURKA in cancer: Molecular mechanisms and opportunities
for cancer therapy. Mol Cancer. 20:152021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kraehenbuehl L, Weng CH, Eghbali S,
Wolchok JD and Merghoub T: Enhancing immunotherapy in cancer by
targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol.
19:37–50. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Finck AV, Blanchard T, Roselle CP,
Golinelli G and June CH: Engineered cellular immunotherapies in
cancer and beyond. Nat Med. 28:678–689. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Talukdar FR, di Pietro M, Secrier M,
Moehler M, Goepfert K, Lima SSC, Pinto LFR, Hendricks D, Parker MI
and Herceg Z: Molecular landscape of esophageal cancer:
Implications for early detection and personalized therapy. Ann N Y
Acad Sci. 1434:342–359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng C, Zhou Y, Li H, Xiong T, Li S, Bi
Y, Kong P, Wang F, Cui H, Li Y, et al: Whole-genome sequencing
reveals diverse models of structural variations in esophageal
squamous cell carcinoma. Am J Hum Genet. 98:256–274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Warner SL, Stephens BJ, Nwokenkwo S,
Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H and Von Hoff DD:
Validation of TPX2 as a potential therapeutic target in pancreatic
cancer cells. Clin Cancer Res. 15:6519–6528. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Y, Liu Y, Tan X, Yu S and Luo J:
TPX2 as a novel prognostic indicator and promising therapeutic
target in triple-negative breast cancer. Clin Breast Cancer.
19:450–455. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang H, Wang J, Tian Y, Xu J, Gou X and
Cheng J: The TPX2 gene is a promising diagnostic and therapeutic
target for cervical cancer. Oncol Rep. 27:1353–1359.
2012.PubMed/NCBI
|
|
20
|
Eyers PA, Erikson E, Chen LG and Maller
JL: A novel mechanism for activation of the protein kinase Aurora
A. Curr Biol. 13:691–697. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bayliss R, Sardon T, Vernos I and Conti E:
Structural basis of Aurora-A activation by TPX2 at the mitotic
spindle. Mol Cell. 12:851–862. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sillars-Hardebol AH, Carvalho B, Tijssen
M, Beliën JA, de Wit M, Delis-van Diemen PM, Pontén F, van de Wiel
MA, Fijneman RJ and Meijer GA: TPX2 and AURKA promote 20q
amplicon-driven colorectal adenoma to carcinoma progression. Gut.
61:1568–1575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi Y, Sheridan P, Niida A, Sawada
G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y,
et al: The AURKA/TPX2 axis drives colon tumorigenesis cooperatively
with MYC. Ann Oncol. 26:935–942. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang DH, Jian J, Li S, Zhang Y and Liu
LZ: TPX2 silencing exerts anti-tumor effects on hepatocellular
carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol
Med. 44:2113–2122. 2019.PubMed/NCBI
|
|
25
|
Nagel S, Pommerenke C, MacLeod RAF, Meyer
C, Kaufmann M and Drexler HG: The NKL-code for innate lymphoid
cells reveals deregulated expression of NKL homeobox genes HHEX and
HLX in anaplastic large cell lymphoma (ALCL). Oncotarget.
11:3208–3226. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Engeland K: Cell cycle arrest through
indirect transcriptional repression by p53: I have a DREAM. Cell
Death Differ. 25:114–132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krause K, Wasner M, Reinhard W, Haugwitz
U, Dohna CL, Mössner J and Engeland K: The tumour suppressor
protein p53 can repress transcription of cyclin B. Nucleic Acids
Res. 28:4410–4418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engeland K: Cell cycle regulation:
p53-p21-RB signaling. Cell Death Differ. 29:946–960. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Connor OA, Özcan M, Jacobsen ED, Roncero
JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R,
Beaven A, et al: Randomized phase III study of alisertib or
investigator's choice (selected single agent) in patients with
relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol.
37:613–623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Melichar B, Adenis A, Lockhart AC,
Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A,
Zatloukal P, Zhang B, et al: Safety and activity of alisertib, an
investigational aurora kinase A inhibitor, in patients with breast
cancer, small-cell lung cancer, non-small-cell lung cancer, head
and neck squamous-cell carcinoma, and gastro-oesophageal
adenocarcinoma: A five-arm phase 2 study. Lancet Oncol. 16:395–405.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grover A, Singh R, Shandilya A, Priyandoko
D, Agrawal V, Bisaria VS, Wadhwa R, Kaul SC and Sundar D:
Ashwagandha derived withanone targets TPX2-Aurora A complex:
Computational and experimental evidence to its anticancer activity.
PLoS One. 7:e308902012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Federico L, McGrail DJ, Bentebibel SE,
Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A,
Negrao MV, et al: Distinct tumor-infiltrating lymphocyte landscapes
are associated with clinical outcomes in localized non-small-cell
lung cancer. Ann Oncol. 33:42–56. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Loi S, Michiels S, Adams S, Loibl S,
Budczies J, Denkert C and Salgado R: The journey of
tumor-infiltrating lymphocytes as a biomarker in breast cancer:
Clinical utility in an era of checkpoint inhibition. Ann Oncol.
32:1236–1244. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okadome K, Baba Y, Yagi T, Kiyozumi Y,
Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M and Baba
H: Prognostic nutritional index, tumor-infiltrating lymphocytes,
and prognosis in patients with esophageal cancer. Ann Surg.
271:693–700. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blas-Rus N, Bustos-Morán E, Pérez de
Castro I, de Cárcer G, Borroto A, Camafeita E, Jorge I, Vázquez J,
Alarcón B, Malumbres M, et al: Aurora A drives early signalling and
vesicle dynamics during T-cell activation. Nat Commun. 7:113892016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bustos-Morán E, Blas-Rus N, Alcaraz-Serna
A, Iborra S, González-Martínez J, Malumbres M and Sánchez-Madrid F:
Aurora A controls CD8+ T cell cytotoxic activity and
antiviral response. Sci Rep. 9:22112019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han J, Jiang Z, Wang C, Chen X, Li R, Sun
N, Liu X, Wang H, Hong L, Zheng K, et al: Inhibition of Aurora-A
promotes CD8+ T-cell infiltration by mediating IL10
production in cancer cells. Mol Cancer Res. 18:1589–1602. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin T, Zhao ZB, Guo J, Wang T, Yang JB,
Wang C, Long J, Ma S, Huang Q, Zhang K, et al: Aurora A inhibition
eliminates myeloid cell-mediated immunosuppression and enhances the
efficacy of anti-PD-L1 therapy in breast cancer. Cancer Res.
79:3431–3444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Punt S, Malu S, McKenzie JA, Manrique SZ,
Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL,
Dominguez AL, et al: Aurora kinase inhibition sensitizes melanoma
cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother.
70:1101–1113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Basu A, Ramamoorthi G, Albert G, Gallen C,
Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ and Kodumudi K:
Differentiation and regulation of TH cells: A balancing
act for cancer immunotherapy. Front Immunol. 12:6694742021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sammarco G, Varricchi G, Ferraro V,
Ammendola M, De Fazio M, Altomare DF, Luposella M, Maltese L, Currò
G, Marone G, et al: Mast cells, angiogenesis and lymphangiogenesis
in human gastric cancer. Int J Mol Sci. 20:21062019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Majorini MT, Colombo MP and Lecis D: Few,
but efficient: The role of mast cells in breast cancer and other
solid tumors. Cancer Res. 82:1439–1447. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y,
Xu J, Rao H, Chen S, Zhang L and Zheng L: Mast cells expressing
interleukin 17 in the muscularis propria predict a favorable
prognosis in esophageal squamous cell carcinoma. Cancer Immunol
Immunother. 62:1575–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
